Status
Conditions
Treatments
About
The purpose of this protocol is to provide compassionate use of Kedrion Human Plasminogen Ophthalmologic Drops to an expanded population of patients diagnosed with ligneous conjunctivitis associated with type I Plasminogen deficiency until product licensure, and/or until a new clinical trial is available and the patients in treatment under Expanded Access are eligible to participate in the new trial.
Sex
Volunteers
Inclusion criteria
Exclusion criteria
Loading...
Central trial contact
Laura Pino; Anna Lotti Suffredini
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal